The device has been designed to detect even the hardest to detect cardiac episodes, including atrial filbrillation (AF) and will suggest appropriate steps to follow. The device continuously monitors a patient’s heart rhythm  and transits important readings in real time, allowing physicians to keep a good check on their patients remotely and an in a accurate manner. The ICM device has already attained a CE and USFDA approval and is available in Australia, USA and European Union nations.  

 

General Manager of Abbott –St. Jude, India & Subcontinent, Ajay Singh Chauhan said, “This new ICM provides patients a new way to monitor for abnormal heart rhythms while staying connected to their physician remotely and engaged in their health care. For physicians, the device allows for effective management of patients while enhancing patient compliance through smartphone connectivity. If left undetected, arrhythmias can lead to additional – and often serious – complications for patients.”

 

The device needs to be implemented under the skin of the chest in a minimally-invasive outpatient procedure. It will then monitor heart rhythms at a constant rate to detect a wide range of cardiac arrhythmias.

 

While the ICM continuously monitors for abnormal heart rhythms and transmits data to a patient’s physician, the app also allows patients to track symptoms proactively, sync their data with their clinic at any time, and view their transmission history without having to contact their clinic to confirm successful data transfers.